Tulos

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tulos

Understanding Tulos

Tulos is a medication belonging to a class of drugs known as parathyroid hormone-related protein (PTHrP) analogs. It is a synthetic form of a naturally occurring protein in the body that plays a critical role in regulating calcium levels and bone metabolism.

Mechanism of Action

The primary function of Tulos is to stimulate bone formation. It works by activating specific receptors on the surface of osteoblasts, which are the cells responsible for building new bone tissue. By increasing the activity and number of these cells, the medication helps to improve bone density and strengthen the skeletal structure over time.

Unlike some other bone-related treatments that primarily focus on slowing down bone loss, Tulos is characterized as an anabolic agent, meaning its main purpose is to actively promote the growth of new bone.

Clinical Application

Tulos is utilized in clinical settings to manage conditions characterized by significant bone weakness or a high risk of fractures. It is typically considered for individuals who have a history of bone fragility or those who have not seen sufficient results from other bone-modifying therapies.

The goal of treatment with Tulos is to increase bone mineral density, particularly in the spine and hip, to reduce the likelihood of future skeletal injuries. Because of its specific mechanism, the duration of use is generally limited to a defined period as determined by a healthcare provider.

What side effects are possible with Tulos?

Official Safety Profile and Adverse Reactions

The officially documented adverse effects for Tulos (Lactulose) are primarily localized to the Gastrointestinal Disorders system, aligning with the medicine's non-systemic, osmotic action within the colon. The severity and occurrence of these events are categorized according to regulatory standards (e.g., EMA SmPC, FDA labeling).

Classification Adverse Reactions (Examples)
Very Common Flatulence, Diarrhoea (dose-related)
Common Abdominal pain, Nausea, Vomiting
Uncommon Electrolyte imbalance (resulting from diarrhoea)

Adverse reactions involving the Metabolism and Nutrition Disorders system are explicitly tied to the potential for excessive dosage. High or chronic, unadjusted use may lead to significant fluid loss, potentially causing serious complications such as hypokalemia (low potassium) and hypernatremia (high sodium).

Safety Considerations and Restrictions

Certain safety patterns are documented based on exposure. Flatulence is frequently reported during the first days of treatment but typically subsides as treatment continues. The risk of electrolyte disturbance is primarily associated with high doses or extended treatment duration (e.g., over six months), for which periodic serum electrolyte monitoring is indicated in populations like older adults.

Regulatory documents stipulate absolute restrictions for use. Tulos is contraindicated in patients with Galactosemia, due to the presence of related sugars in the formulation. It is also prohibited in cases of confirmed or suspected gastrointestinal obstruction or digestive perforation, as stated in official labeling.

Overdose and Emergency Response

Taking more than the prescribed dose of Tulos (Lactulose) can lead to an overdose, although there are no reports of accidental overdosage being fatal. Tulos is a synthetic disaccharide osmotic laxative, and its primary overdose effects are related to excessive laxation and subsequent fluid and electrolyte imbalance.

Symptoms of Overdose

The major symptoms associated with an acute overdose of Tulos are primarily gastrointestinal:

  • Diarrhea (severe and persistent)
  • Abdominal pain and cramping

Abuse or prolonged, excessive use can lead to a more serious complication: loss of essential body electrolytes, particularly potassium. Symptoms of severe electrolyte loss may include muscle weakness, confusion, irregular heartbeat, and increased thirst.

When to Seek Emergency Help

If you or someone else has taken more Tulos than recommended, immediately contact emergency medical services or a poison control center for advice, even if symptoms are not yet apparent.

Seek immediate emergency medical attention if the person exhibits any signs of severe dehydration or electrolyte imbalance, such as:

Symptom Description
Severe Dehydration Extreme thirst, reduced urination, dizziness, or fainting.
Electrolyte Imbalance Confusion, significant muscle weakness, or a very fast, pounding, or irregular heartbeat.

In the event of an overdose, do not wait for severe symptoms to appear. Prompt medical evaluation is necessary to address fluid loss and restore electrolyte balance.

Therapeutic Uses of Tulos

What Tulos Treats: Main Uses and Benefits

Tulos (Lactulose) is applied in addressing certain distressing symptoms across two key therapeutic domains, generally used when supportive symptom management is appropriate. The medication is commonly used to help with both chronic gastrointestinal issues and a specialized metabolic condition.


Easing Chronic Difficulties with Bowel Evacuation

Tulos is commonly used across conditions involving recurrent or episodic manifestations of constipation, helping address symptom clusters such as hard, dry stools and straining at defecation. It is relevant for easing symptoms that interfere with daily comfort, and helps patients cope more steadily with difficult episodes. The conditions commonly managed include chronic constipation, support for patients with hemorrhoids, and assistance with opioid-associated bowel regulation. Tulos is generally applied when appropriate for managing constipation in patient groups like older adults and children.

“Tulos supports patients during episodes of heightened discomfort related to hard, infrequent stools.”


Managing Neuropsychiatric Symptoms of Liver Disease

This medication is also applicable within clinical settings that involve acute or disruptive symptom patterns for symptoms related to systemic imbalance, specifically for Neuropsychiatric Symptoms associated with Hepatic Encephalopathy (HE). Tulos supports patients during episodes of heightened discomfort. This action is applied in addressing symptoms related to systemic imbalance and may assist with maintaining functional stability, thereby supporting general well-being during symptomatic phases affected by severe liver disease.


Quick Fact: Targeting Symptoms of Straining at Defecation

Tulos is applied across domains where additional symptomatic support is needed, primarily to ease the symptom clusters of constipation and to manage the neurological manifestations of Hepatic Encephalopathy.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Tulos?

This section outlines the official eligibility and exclusion criteria for Tulos (Lactulose), based strictly on government regulatory labeling (e.g., FDA, EMA SmPC).


Absolute Contraindications

Tulos is contraindicated and must not be used by individuals with the following conditions:

  • Galactosaemia or other severe hereditary problems involving intolerance or malabsorption of the sugars contained in Lactulose.
  • Confirmed or suspected Gastrointestinal Obstruction or Perforation (e.g., a bowel blockage).
  • Acute Inflammatory Bowel Disease, such as severe Ulcerative Colitis or Crohn's Disease.
  • Known Hypersensitivity to the active ingredient, Lactulose, or any of its excipients.

Eligibility for Specific Populations

Population Group Official Regulatory Status
Pregnancy and Breastfeeding Permitted. Use is allowed due to negligible systemic absorption.
Adults and Adolescents Approved for general use in both constipation and Hepatic Encephalopathy (HE).
Children and Infants Conditional Use. Approved for constipation but requires medical supervision for use as a laxative.
Children (HE indication) Use Not Established. Safety and effectiveness for treating HE in this age group have not been established.
Patients with Diabetes Conditional Use. Caution is advised, particularly with the high doses used for HE.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Tulos (Lactulose) is defined by interactions that occur primarily in the gastrointestinal tract and those related to fluid and electrolyte balance; systemic pharmacokinetic (CYP/transporter) interactions are not documented.

Interaction Scope Details from Official Regulatory Documents
Contraindicated Combination Use is formally restricted in patients who require a low galactose diet.
Mechanistic Basis Electrolyte disturbance, modification of colonic pH, and bacterial flora interference.

Official interaction statements:

  • Co-administration with non-absorbable antacids may inhibit the desired colonic pH drop, which is officially noted as a consideration for a possible lack of desired treatment effect.
  • Anti-infective agents, such as Neomycin, may theoretically interfere with the colonic bacterial action necessary for Lactulose's function, potentially resulting in an inadequate therapeutic response.
  • The potential for hypokalemia (potassium loss) is the basis for documented pharmacodynamic interactions. Lactulose may increase potassium loss induced by other drugs, including thiazide diuretics, steroids, and Amphotericin B.
  • This electrolyte disturbance is clinically relevant because hypokalemia can potentiate the effects of cardiac glycosides (e.g., Digoxin).

Population-specific interaction notes:

  • For elderly or debilitated patients receiving chronic therapy for more than six months, periodic measurement of serum electrolytes is formally required due to the risk of prolonged potassium loss.

Connection to the overall interaction profile: The regulatory documents define the product’s interaction structure by focusing on the reduction in efficacy due to interference with the colonic environment, and the potentiation of other drugs due to a risk of hypokalemia.

Mechanism of Action

Osmotic Mechanism and Fluid Regulation

The active ingredient, Lactulose, is a non-absorbable synthetic disaccharide that resists enzymatic hydrolysis in the small intestine, reaching the colon intact. Here, the non-absorbed solute creates a powerful osmotic gradient across the intestinal mucosa. This gradient actively drives water from the surrounding tissue into the colonic lumen. This action initiates a cascading physical effect, resulting in the increased fluid content and overall volume of the intestinal contents.


Microbial Activation and Motility Enhancement

The secondary physiological consequence begins when the molecule interacts with its biological target: the indigenous colonic bacteria. These bacteria anaerobically ferment Lactulose into short-chain fatty acids (SCFAs), which further amplify the osmotic pressure and cause the contents to become acidified (lowered pH). The resultant large volume and distension of the colon wall mechanically stimulate the intestinal smooth muscle, directly enhancing colonic motility and peristaltic contractions. The necessity of this bacterial activation and full intestinal transit is why the change in physiological function is inherently time-delayed (24–48 hours) following administration.

Dosage and Administration Information

Tulos is administered primarily as an Oral Solution or Syrup, although a specialized Rectal route may be used as an enema in specific circumstances related to Hepatic Encephalopathy (HE). The medication is designed for intake with or without food and can be taken undiluted or mixed with water, fruit juice, or milk to aid consumption. To support its action, consumption of sufficient fluids, typically 1.5 to 2 liters daily, is recommended during the period of use.

The administration schedule is strictly dependent on the approved condition. For constipation, Tulos is commonly taken once daily or in two divided doses, with a usual starting dose ranging from 15 mL to 45 mL (10 g to 30 g). The dose is then adjusted to a maintenance level, often 15 mL to 30 mL daily. This usage is generally short-term or intermittent.

For the management of Hepatic Encephalopathy, the use pattern is significantly different, commencing with a higher initial oral dose of 30 mL to 45 mL (20 g to 30 g) taken three to four times daily. Critically, the dosing is then titrated (adjusted) every one to two days until a specific response—the production of two to three soft stools daily—is consistently achieved. Usage for this condition often follows a long-term, continuous pattern to sustain the effect. Use in children should be exceptional and monitored. If a dose is missed, the next scheduled dose should be taken at the usual time without doubling up.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Tulos

Evidence for Use in Chronic Constipation

Tulos was studied in clinical trials involving patients with chronic constipation. Researchers structured these trials to evaluate the agent primarily against an inactive substance (placebo) or against other agents that influence bowel function.

Studies included a variety of populations, encompassing adults, older adults, and separate trials involving children (pediatric constipation). These trials used defined, short-term intervals for observation, often spanning between one and six weeks. The key outcomes describing episodic or acute changes that were monitored included the frequency of spontaneous bowel movements (SBMs) per week and objective measures of stool consistency.

Findings describe patterns observed in the studies where participants who received the agent demonstrated changes in these measurements. Research highlights changes measured during the short study period, with measurements related to stool consistency being observed. Systematic reviews of comparative studies have noted that measurements of clinical parameters and patient-reported outcomes may vary across different trials and populations.


Evidence for Management of Hepatic Encephalopathy (HE)

Tulos was studied in clinical trials involving patients with liver cirrhosis who were experiencing Hepatic Encephalopathy (HE), which involves outcomes related to systemic or functional imbalance. Studies were structured as randomized trials to assess the agent’s role in managing an acute episode of HE and also to observe its use in research contexts involving preventing recurrent episodes.

The populations studied were adults with cirrhosis, and the research monitored outcomes reflecting daily functioning or activity level. Researchers primarily tracked changes in the neurological grade of the condition, using standardized clinical scales, alongside monitoring measurements related to blood ammonia levels.

Research describes patterns where the measured severity of the acute HE episode was observed to change according to the study protocol. Research monitored measurements related to blood ammonia levels during the observed period. In prevention studies, research examined outcomes reflecting the frequency of subsequent HE episodes among participants who received the agent. Findings were mixed across the broader clinical literature regarding the comparative profile of Tulos with other established prevention treatments.


Consistency of Evidence and Research Gaps

Overall, the research for Tulos contributes to the broader evidence landscape, but its certainty remains low in several key areas. Evidence quality varies across studies, with some older trials having different methods than newer research. In some cases, sample sizes were modest, meaning the results apply only to the populations studied and may not be generalizable to everyone. Research limitations include the limited availability of long-term data for both indications, as well as the limited availability of certain types of comparative evidence.

Key Studies & References

  1. The treatment of chronic constipation in adults: a systematic review
  2. Comparative Effectiveness and Safety of Polyethylene Glycol Electrolyte Solution Versus Lactulose for Treatment of Hepatic Encephalopathy: A Systematic Review and Meta-analysis
  3. Lactulose - StatPearls (for Hepatic Encephalopathy context, outcomes, and special populations)

Frequently Asked Questions (FAQ)

Common questions about Tulos (FAQ)


Q: Does Tulos cure the condition or just manage the symptoms?

Official product information describes Tulos as being used for the treatment and management of chronic constipation and Hepatic Encephalopathy (HE). Because of its physiological action, its primary purpose is to manage symptoms and physiological function associated with these conditions rather than providing a cure for the underlying disease.


Q: What is the main difference between Tulos and similar medicines?

Tulos is chemically classified as an osmotic laxative. This means it works by drawing water into the colon to soften stool and encourage movement. This is a non-stimulant approach, differing from stimulant laxatives that directly trigger muscle contractions in the bowel.


Q: Can Tulos cause long-term health problems?

Official warnings highlight that chronic or excessive, unadjusted use may lead to electrolyte disturbances, such as low potassium (hypokalemia) and high sodium (hypernatremia). These are metabolic complications that require careful monitoring, particularly in older or debilitated patients receiving extended therapy.


Q: Are there any known serious side effects from Tulos?

Serious complications are primarily linked to severe fluid loss and electrolyte imbalance, which can happen with excessive dosing. Additionally, official documents mention a theoretical hazard for patients undergoing certain medical procedures, such as electrocautery during a colonoscopy, due to potential gas accumulation.


Q: I feel different after starting Tulos; is this a normal adjustment period?

Regulatory documents indicate that common side effects like flatulence and intestinal cramps may occur during the initial days of treatment. These effects are usually transient and often subside as the body adjusts and treatment continues.


Q: What should a patient look out for as a sign of a serious reaction to Tulos?

Signs of severe fluid and electrolyte loss resulting from persistent diarrhea, as noted in clinical guidance, include dizziness, confusion, and excessive thirst. These symptoms are typically noted as requiring attention from a healthcare professional.


Q: Is Tulos safe for older people to take?

Use in older individuals may require caution. Older or debilitated patients receiving chronic therapy may be at an increased risk of adverse metabolic effects from fluid loss. Due to this risk, regulatory guidance requires periodic monitoring of serum electrolytes for these individuals.


Q: Does a history of heart disease affect eligibility for Tulos?

Heart disease history itself is not listed as an absolute contraindication. However, official drug interaction statements note that the risk of low potassium (hypokalemia) can potentiate the effects of certain heart medications, such as cardiac glycosides (like Digoxin).


Q: Is Tulos suitable for people who have allergies to other medications?

Tulos is formally contraindicated only in patients with known hypersensitivity to the active ingredient (Lactulose) or any of its excipients. Allergies to other, unrelated medications are not specifically addressed as an exclusion criterion in the official labeling.


Q: Why do doctors prescribe Tulos over other options? (Non-comparative rationale)

The active ingredient in Tulos is often used because it is poorly absorbed from the gastrointestinal tract. This mechanism is desirable as it means the medicine works locally in the colon and is not known to exert systemic effects on the rest of the body.


Q: How does the body break down and eliminate Tulos?

The medicine is minimally absorbed into the bloodstream. The small amount absorbed (3% or less) is eliminated in the urine. The majority of the dose reaches the colon where it is broken down by bacteria into acids, and then eliminated through the stool.


Q: What is the current research consensus on the long-term effectiveness of Tulos?

Regulatory reviews indicate that the certainty of evidence varies across the clinical trials that have been conducted. Research limitations include a limited availability of long-term data to establish a definitive consensus on chronic use effectiveness outside of clinical trial settings.


Q: Where can I find the official regulatory document for Tulos?

Official, detailed drug information can be found in documents published by government agencies. These documents include the FDA labeling (DailyMed) in the United States or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).


Q: Is weight gain a possible side effect of Tulos?

Weight gain is not listed as a common or known adverse reaction in the official regulatory documents. However, common side effects include abdominal bloating and gas, which are expected gastrointestinal effects of the medicine.


Q: Does Tulos affect sleep patterns?

Sleep pattern changes or sleep disorders are not listed as a common or known adverse reaction in the official regulatory documents for Tulos.


Q: Does Tulos cause dependency or addiction?

Because the active ingredient in Tulos is minimally absorbed into the bloodstream and works locally in the gut, it is not known to cause systemic dependence or addiction.


Q: Are headaches a common complaint when taking Tulos?

Headaches are not listed among the very common, common, or known serious side effects in the official regulatory documents for Tulos.


Q: Can I drink alcohol while taking Tulos?

According to official regulatory documents, there are no known specific interactions listed between Tulos and alcohol.


Q: Does Tulos interact with commonly used over-the-counter pain relievers?

Official interaction statements indicate that there are no known specific interactions listed between Tulos and common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen.


Q: Does Tulos interact with herbal supplements like St. John's Wort?

There are no known specific interactions listed in the official regulatory documents between Tulos and common herbal supplements, including St. John's Wort.


Q: Is it safe to drive or operate machinery while taking Tulos?

Official product information states that Tulos is not known to affect a patient's ability to drive or operate machinery.


Q: Does Tulos affect birth control effectiveness?

There are no known specific interactions listed in the regulatory documents between Tulos and hormonal birth control products.


Q: Are people with kidney problems allowed to take Tulos?

Official information indicates that use in people with reduced kidney function may require caution. These individuals may be at an increased risk of adverse effects from fluid and electrolyte disturbances if excessive dosage is used.


Q: Is Tulos available as a generic medicine?

Yes, the active ingredient in Tulos is widely available. The FDA categorizes this substance as an Abbreviated New Drug Application (ANDA) product, which confirms the availability of generic versions under various trade names.


Q: Is it safe to stop taking Tulos suddenly?

Tulos can typically be stopped abruptly without the need for tapering, as it works locally and is not associated with systemic dependence. The focus should be on monitoring for the recurrence of the condition that the medicine was treating.


Q: Can Tulos make me feel dizzy or lightheaded?

While dizziness or lightheadedness are not listed as common side effects, they can be signs of the serious complication of fluid and electrolyte loss resulting from excessive diarrhea. These symptoms are typically noted as requiring attention from a healthcare professional.

How should Tulos be stored and disposed of?

Tulos (Lactulose Solution) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure safety.


Storage Requirements

Temperature and Protection: Store the solution at a Controlled Room Temperature, typically between 20 C and 25 C (68 F to 77 F). It is mandatory to avoid freezing the product, as this may cause the sugar components to crystallize. The medicine must be stored in its original container and kept tightly closed.

Stability: The solution may darken in color upon storage, but this does not affect its action. Do not use the product if the container seal is broken.

Child Safety: Keep the medicine out of the sight and reach of children.


Disposal Instructions

Dispose of unused or expired Tulos according to the official instructions provided by the FDA or local law enforcement, often through authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tulos found in:

A-Z Index: